# P2.14-51 Dual ALK Fusion Partners as Poor Predictive Marker in First Line Crizotinib Treated ALK Rearranged Non-Small Cell Lung Cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/p2-14-51-dual-alk-fusion-partners-as-poor-predictive-marker-in-first-line/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yisheng Zhang,L. Zeng,Nong Yang,Tao Jiang,C.Z. Zhou |
| Citations | 2 |
| DOI | 10.1016/j.jtho.2019.08.1836 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2982154458 |
| Type | article |
| Year | 2019 |

## Paper authors

- [L. Zeng](https://scholariq.org/researchers/l-zeng/)

## Paper journal

- [Journal of Thoracic Oncology](https://scholariq.org/journals/journal-of-thoracic-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.